Fusion Capital’s Akebia Therapeutics AKBA Stock Holding History

Fusion Capital’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-10,561	Closed	-$67K	–	54
2019 Q4	$67K	Buy	+10,561	New	+$50.2K	0.06%	64

Other funds holding AKBA

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fusion Capital's AKBA Position: Q1 2020 in Review

Fusion Capital sold out of Akebia Therapeutics (AKBA) in Q1 2020, closing a stake of 10,561 shares — an estimated $67K sold.

Fusion Capital first reported a position in AKBA in Q4 2019 and held it in 1 quarter. The position peaked at $67K in Q4 2019. 155 funds tracked by Wall St. Rank hold AKBA as of Q1 2020.

Fusion Capital reported no remaining Akebia Therapeutics position as of Q1 2020 after selling out during the quarter.
Fusion Capital sold 10,561 Akebia Therapeutics shares in Q1 2020, an estimated $67K.
Fusion Capital first reported a position in Akebia Therapeutics in Q4 2019 and held it in 1 quarter.
Fusion Capital's Akebia Therapeutics position peaked at $67K in Q4 2019.
155 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2020.

Based on Fusion Capital's 13F filing for Q1 2020, filed 15 May 2020.